Vyvanse patent expiration?

Vyvanse (lisdexamfetamine dimesylate) is protected by multiple patents and regulatory exclusivities, not a single expiration date. In the U.S. the protection comes from a mix of:

- Core composition/formulation patents for lisdexamfetamine dimesylate
- Related method-of-use and formulation patents
- Pediatric exclusivity and other regulatory exclusivities that can extend protection beyond the base patent term

Because these can expire at different times, there isn’t one simple date. In practice, the core composition patents tended to expire in the 2018–2019 window, but pediatric exclusivity and other patents extended brand protection into the early-to-mid 2020s. Generics began to enter in some cases around 2023–2024, depending on settlements and market.

If you want precise dates for the U.S. (and want to know about other jurisdictions), I can look up the exact patent expiration dates in the FDA Orange Book and list each patent and its expiration. Would you like me to pull the exact dates and specify US vs. worldwide status?